Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Prilosec

Executive Summary

Is "approvable" for use in the short-term treatment of active duodenal ulcer poorly responsive to customary medical therapy. Merck reportedly received the approvable letter Dec. 26. An FDA advisory committee recommended approval for treatment of short- term acute and refractory duodenal ulcers in May 1990. The acid pump inhibitor was approved in 1989 for three limited indications: short-term treatment of severe erosive esophagitis, short-term treatment of symptomatic gastroesophageal reflux disease poorly responsive to customary medical treatment, and long-term treatment of Zollinger-Ellison syndrome.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel